Two phenothiazine compounds, trifluoperazine and chlorpromazlnej inhibited growth in vitro of the five niost common pathogenic yeasts, with MICs ranging from 10 to 40 uLg/ml. Daily intraperitoneal injections of trifluoperazine (4 to 7 mg/kg of body weight) increased the survival of mice experimentally infected with Candida albicans or Cryptococcus neoformans. The potential use of these drugs against fungal meningitis is discussed.
The increasing occurrence of mycoses caused by opportunistic systemic infections (2, 3, 7) and the lack of effective and safe drugs (8) led to the search for new antifungal drugs with low toxicity. In previous studies in our laboratory, we investigated the effects and the mechanism of action of compounds from the phenothiazine group on the yeast Saccharomyces cerevisiae (4) (5) (6) . It was found that trifluoperazine (TFP) and chlorpromazine (CPZ) cause a quick and massive K+ efflux leading to membrane hyperpolarization, Ca2' influx, and inhibition of the plasma membrane H+-ATPase. The results led to the suggestion that these substances, which are currently used as tranquilizers and in antipsychotic therapy (1) , may be used as drugs against pathogenic yeasts in systemic infections. Since the phenothiazines accumulate in the central nervous system (1, 2) , these drugs may be specifically effective against fungal meningitis and encephalitis. In the present study, we investigate the activity of TFP and CPZ against five medically important yeasts.
The yeasts used in the experiments were isolated from clinical specimens taken from different body sites of patients before treatment. Only one isolate per patient was studied. The yeasts were identified to the species level by current conventional methods (11) . The isolates were maintained on Sabouraud dextrose agar until tested. In each in vitro experiment, at least five isolates of each species were tested. The mice used for in vivo experiments were Sabra white female mice 20 to 25 g in weight, and each experiment was repeated three times.
MICs were determined by the agar dilution method as described previously (10) Since both CPZ and TFP are currently used as pharmaceutical compounds, toxicity was not investigated extensively. In one experiment, we observed that a single i.p. injection dose of 283 mg of TFP per kg of body weight into noninfected mice caused a visible tranquilizing effect 1 day postinjection. There was no effect on their survival. Daily i.p. injections of 56 mg of TFP per kg of body weight into noninfected mice over 30 days did not affect their survival and had a mild tranquilizing effect on these mice.
Opportunistic fungal infections represent an increasing threat, mainly to immunosuppressed patients (2, 3, 15) . Yet the few drugs available have limited efficiency or moderate toxicity (8, 12, 13) . The problem is particularly severe in fungal meningitis since amphotericin B, the most efficient antifungal drug available, poorly penetrates the blood-brain barrier (8) .
The phenothiazines are a group of potent pharmacological agents with neuroleptic, antiemetic, antihistaminic, anticholinergic, and sedative activities (1, 14) . Their main pharmacological effect is determined by variations in the chemical structure of the side chain at position 10 of the phenothiazine ring. In t,he present study, two of these compounds, TFP and CPZ, inhibited growth in vitro of five pathogenic yeasts.
In mice infected experimentally with C. neoformans or C. albicans, daily injections of TFP caused an increase in the survival time. The lower doses used in these in vivo experiments were of the same order of magnitude as the therapeutic doses of these substances. Since the phenothiazines accumulate in the central nervous system and since their concentration in the brain may reach 10 times the concentration in serum (9) , these substances may be particularly suitable, after additional research, for treatment of fungal meningitis and encephalitis caused by pathogens, mainly those resistant to flucytosine, since a high frequency of resistance to flucytosine has been reported (13) .
It was recently suggested that phenothiazines such as CPZ, TFP, and others may be given to cancer patients to reduce the chemotherapy-induced emesis (14) . It would be beneficial to determine whether these drugs, when administered as antiemetics, also have prophylactic effects in fungal infections, which are common in cancer patients (2) .
The yeast S. cerevisiae has a susceptibility to TFP similar to that of C. albicans. The mechanism of action of TFP on S. cerevisiae has been investigated recently in our laboratory (4) (5) (6) . It was found that TFP affects yeast cell membranes within 30 min of addition by causing K+ efflux, membrane hyperpolarization, increased Ca2W influx, and inhibition of the plasma membrane H+-ATPase. The membranedamaging effects were most pronounced above pH 7.0 (6). In addition to these effects, it was found that low concentrations of TFP, which did not cause membrane damage, caused an arrest of cell growth at specific points of the cell cycle (Y. Eilam and D. Chernichovsky, unpublished results). Thus, the mechanism of action of the phenothiazine on susceptible yeasts involved both membrane damage and interference with the cell cycle.
There is a potential for using phenothiazines as drugs against systemic yeast infections and particularly in the treatment of fungal meningitis, but further investigation is required.
